Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

156

Participants

Timeline

Start Date

February 15, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Type 2 DiabetesNon-Alcoholic Fatty Liver Disease

Interventions

DRUG

Henagliflozin

Besides lifestyle intervention and background medication, participants will be prescribed Henagliflozin at standard clinical doses.

OTHER

Background medication

Participants will only receive lifestyle intervention and background medication.

All Listed Sponsors

lead

Sir Run Run Shaw Hospital

OTHER